Drug
Bcx10013
Bcx10013: highest development phase Phase 1, developed by BioCryst Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- BioCryst Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| BCX10013 NCT06100900 | Phase 1 | Paroxysmal Nocturnal Hemoglobinuria |
Latest
No recent events.
Follow Bcx10013 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.